Literature DB >> 33780038

An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.

Nicholas J Short1, Marina Konopleva1, Tapan Kadia1, Partow Kebriaei2, Naval Daver1, Xuelin Huang3, Lucia Masarova1, Robin Cook1, Nitin Jain1, Elias Jabbour1, Hagop Kantarjian1, Farhad Ravandi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33780038      PMCID： PMC9278812          DOI： 10.1002/ajh.26175

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   13.265


× No keyword cloud information.
  14 in total

Review 1.  Pathways and mechanisms of venetoclax resistance.

Authors:  Prithviraj Bose; Varsha Gandhi; Marina Konopleva
Journal:  Leuk Lymphoma       Date:  2017-01-31

2.  Ibrutinib and Venetoclax for First-Line Treatment of CLL.

Authors:  Nitin Jain; Michael Keating; Philip Thompson; Alessandra Ferrajoli; Jan Burger; Gautam Borthakur; Koichi Takahashi; Zeev Estrov; Nathan Fowler; Tapan Kadia; Marina Konopleva; Yesid Alvarado; Musa Yilmaz; Courtney DiNardo; Prithviraj Bose; Maro Ohanian; Naveen Pemmaraju; Elias Jabbour; Koji Sasaki; Rashmi Kanagal-Shamanna; Keyur Patel; Jeffrey Jorgensen; Naveen Garg; Xuemei Wang; Katrina Sondermann; Nichole Cruz; Chongjuan Wei; Ana Ayala; William Plunkett; Hagop Kantarjian; Varsha Gandhi; William Wierda
Journal:  N Engl J Med       Date:  2019-05-30       Impact factor: 91.245

3.  Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.

Authors:  Kirsten Fischer; Othman Al-Sawaf; Jasmin Bahlo; Anna-Maria Fink; Maneesh Tandon; Mark Dixon; Sandra Robrecht; Simon Warburton; Kathryn Humphrey; Olga Samoylova; Anna M Liberati; Javier Pinilla-Ibarz; Stephen Opat; Liliya Sivcheva; Katell Le Dû; Laura M Fogliatto; Carsten U Niemann; Robert Weinkove; Sue Robinson; Thomas J Kipps; Sebastian Boettcher; Eugen Tausch; Rod Humerickhouse; Barbara Eichhorst; Clemens-Martin Wendtner; Anton W Langerak; Karl-Anton Kreuzer; Matthias Ritgen; Valentin Goede; Stephan Stilgenbauer; Mehrdad Mobasher; Michael Hallek
Journal:  N Engl J Med       Date:  2019-06-04       Impact factor: 91.245

4.  Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia.

Authors:  Rita Assi; Hagop Kantarjian; Nicholas J Short; Naval Daver; Koichi Takahashi; Guillermo Garcia-Manero; Courtney DiNardo; Jan Burger; Jorge Cortes; Nitin Jain; William Wierda; Salim Chamoun; Marina Konopleva; Elias Jabbour
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2017-08-18

Review 5.  Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors.

Authors:  Iman Abou Dalle; Hagop M Kantarjian; Nicholas J Short; Marina Konopleva; Nitin Jain; Guillermo Garcia-Manero; Rebecca Garris; Wei Qiao; Jorge E Cortes; Susan O'Brien; Partow Kebriaei; Tapan Kadia; Elias Jabbour; Farhad Ravandi
Journal:  Am J Hematol       Date:  2019-10-21       Impact factor: 10.047

6.  Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia.

Authors:  Ohad Benjamini; Theresa Liu Dumlao; Hagop Kantarjian; Susan O'Brien; Guillermo Garcia-Manero; Stefan Faderl; Jeffrey Jorgensen; Rajyalakshmi Luthra; Rebecca Garris; Deborah Thomas; Partow Kebriaei; Richard Champlin; Elias Jabbour; Jan Burger; Jorge Cortes; Farhad Ravandi
Journal:  Am J Hematol       Date:  2014-03       Impact factor: 10.047

7.  Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

Authors:  Andrew W Roberts; Matthew S Davids; John M Pagel; Brad S Kahl; Soham D Puvvada; John F Gerecitano; Thomas J Kipps; Mary Ann Anderson; Jennifer R Brown; Lori Gressick; Shekman Wong; Martin Dunbar; Ming Zhu; Monali B Desai; Elisa Cerri; Sari Heitner Enschede; Rod A Humerickhouse; William G Wierda; John F Seymour
Journal:  N Engl J Med       Date:  2015-12-06       Impact factor: 91.245

8.  10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.

Authors:  Courtney D DiNardo; Abhishek Maiti; Caitlin R Rausch; Naveen Pemmaraju; Kiran Naqvi; Naval G Daver; Tapan M Kadia; Gautam Borthakur; Maro Ohanian; Yesid Alvarado; Ghayas C Issa; Guillermo Montalban-Bravo; Nicholas J Short; Musa Yilmaz; Prithviraj Bose; Elias J Jabbour; Koichi Takahashi; Jan A Burger; Guillermo Garcia-Manero; Nitin Jain; Steven M Kornblau; Philip A Thompson; Zeev Estrov; Lucia Masarova; Koji Sasaki; Srdan Verstovsek; Alessandra Ferrajoli; William G Weirda; Sa A Wang; Sergej Konoplev; Zhining Chen; Sherry A Pierce; Jing Ning; Wei Qiao; Farhad Ravandi; Michael Andreeff; John S Welch; Hagop M Kantarjian; Marina Y Konopleva
Journal:  Lancet Haematol       Date:  2020-09-05       Impact factor: 18.959

9.  A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.

Authors:  J E Cortes; D-W Kim; J Pinilla-Ibarz; P le Coutre; R Paquette; C Chuah; F E Nicolini; J F Apperley; H J Khoury; M Talpaz; J DiPersio; D J DeAngelo; E Abruzzese; D Rea; M Baccarani; M C Müller; C Gambacorti-Passerini; S Wong; S Lustgarten; V M Rivera; T Clackson; C D Turner; F G Haluska; F Guilhot; M W Deininger; A Hochhaus; T Hughes; J M Goldman; N P Shah; H Kantarjian
Journal:  N Engl J Med       Date:  2013-11-01       Impact factor: 91.245

10.  Differential expression of miR-17~92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia.

Authors:  M Scherr; A Elder; K Battmer; D Barzan; S Bomken; M Ricke-Hoch; A Schröder; L Venturini; H J Blair; J Vormoor; O Ottmann; A Ganser; A Pich; D Hilfiker-Kleiner; O Heidenreich; M Eder
Journal:  Leukemia       Date:  2013-11-27       Impact factor: 11.528
View more
  7 in total

Review 1.  Targeting Apoptosis in ALL.

Authors:  Wesley M Smith; Daniel R Reed
Journal:  Curr Hematol Malig Rep       Date:  2022-05-11       Impact factor: 3.952

2.  Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia.

Authors:  Huafeng Wang; Chang Yang; Ting Shi; Yi Zhang; Jiejing Qian; Yungui Wang; Yongxian Hu; Liping Mao; Xiujin Ye; Fang Liu; Zhenfang Xi; Lihong Shou; Caiyun Fu; Hua Naranmandura; Jie Jin; Hong-Hu Zhu
Journal:  Blood Cancer J       Date:  2022-01-28       Impact factor: 11.037

Review 3.  Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Adults.

Authors:  Khalil Saleh; Alexis Fernandez; Florence Pasquier
Journal:  Cancers (Basel)       Date:  2022-04-01       Impact factor: 6.639

4.  INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia.

Authors:  Giovanni Martinelli; Cristina Papayannidis; Alfonso Piciocchi; Valentina Robustelli; Simona Soverini; Carolina Terragna; Giovanni Marconi; Roberto M Lemoli; Fabio Guolo; Antonella Fornaro; Monia Lunghi; Paolo de Fabritiis; Anna Candoni; Carmine Selleri; Federico Simonetti; Monica Bocchia; Antonella Vitale; Luca Frison; Alessandra Tedeschi; Antonio Cuneo; Massimiliano Bonifacio; Maria Paola Martelli; Stefano D'Ardia; Silvia Trappolini; Patrizia Tosi; Piero Galieni; Francesco Fabbiano; Maria Chiara Abbenante; Muriel Granier; Zhaoyin Zhu; Mingyue Wang; Chiara Sartor; Stefania Paolini; Michele Cavo; Robin Foà; Paola Fazi; Marco Vignetti; Michele Baccarani
Journal:  Blood Adv       Date:  2022-03-22

Review 5.  Modern Management Options for Ph+ ALL.

Authors:  Josep-Maria Ribera; Sabina Chiaretti
Journal:  Cancers (Basel)       Date:  2022-09-20       Impact factor: 6.575

Review 6.  B-Lymphoid Blast Phase-Chronic Myeloid Leukemia: Current Therapeutics.

Authors:  Binoy Yohannan; Binsah George
Journal:  Int J Mol Sci       Date:  2022-10-05       Impact factor: 6.208

7.  Impact of frontline treatment approach on outcomes of myeloid blast phase CML.

Authors:  Kapil Saxena; Elias Jabbour; Ghayas Issa; Koji Sasaki; Farhad Ravandi; Abhishek Maiti; Naval Daver; Tapan Kadia; Courtney D DiNardo; Marina Konopleva; Jorge E Cortes; Musa Yilmaz; Kelly Chien; Sherry Pierce; Hagop Kantarjian; Nicholas J Short
Journal:  J Hematol Oncol       Date:  2021-06-15       Impact factor: 17.388
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.